32 completed. 32 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 32 | Completed 32 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 2 |
Follow FOLFIRI: new trials by email Literature Review of FOLFIRI trials Research Report on FOLFIRI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation Onvansertib, FOLFIRI, Bevacizumab - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Completed | Cardiff Oncology | 23 | 2023-03-17 | 2025-01-10 |
| Phase 2 Study of DKN-01 in Colorectal Cancer DKN-01, FOLFIRI, Bevacizumab - Colorectal Cancer, Colorectal Adenocarcinoma | Phase 2 | Completed | Leap Therapeutics, Inc. | 188 | 2022-08-30 | 2025-08-03 |
| A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. Encorafenib, Cetuximab, FOLFIRI - BRAF V600E, Metastatic Colorectal Cancer | Phase 2 | Completed | Pierre Fabre Medicament | 107 | 2021-09-14 | 2026-04-30 |
| MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab Cetuximab, FOLFIRI - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 2 | Completed | TheraOp | 6 | 2020-12-29 | 2025-06-08 |
| Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Selinexor 100 mg, Docetaxel, Pembrolizumab - Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Completed | Karyopharm Therapeutics Inc | 80 | 2020-02-09 | 2026-10-09 |
| Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Onvansertib, Bevacizumab, FOLFIRI - Metastatic Colorectal Cancer, KRAS Gene Mutation | Phase 1 / Phase 2 | Completed | Cardiff Oncology | 68 | 2019-06-24 | 2025-03-04 |
| A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy irinotecan, FOLFIRI - Metastatic Colorectal Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Green Cross Corporation | 53 | 2018-04-02 | 2022-03-03 |
| Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Folfiri-bevacizumab, Folfiri - Neuroendocrine Carcinomas | Phase 2 | Completed | Hospices Civils de Lyon | 153 | 2017-09-04 | 2025-09-03 |
| Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy FOLFIRI, Ramucirumab, Paclitaxel - Advanced Gastric or EGJ Cancer | Phase 2 / Phase 3 | Completed | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 429 | 2017-05-10 | 2026-07-02 |
| Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Veliparib, Placebo, Modified FOLFIRI - Untreated Metastatic Colorectal Cancer | Phase 2 | Completed | AbbVie | 130 | 2014-12-02 | 2018-11-20 |
| Molecularly Tailored Therapy for Pancreas Cancer Gem-OX, Gem-5FU, Gem-Tax - Pancreatic Cancer | Phase 2 | Completed | Georgetown University | 19 | 2012-12-01 | 2018-04-09 |
| Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques panitumumab, FOLFIRI - Stage IV Colorectal Cancer | Phase 2 | Completed | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) | 72 | 2012-10-01 | 2017-08-01 |
| FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma FOLFIRI - Advanced Esophageal Carcinoma | Phase 2 | Completed | Yuhong Li | 35 | 2012-03-01 | 2023-02-16 |
| Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine") Milestone 1: Targeted chemotherapy prior to surgery, Milestone 2: Chemoradiotherapy (cXRT), Milestone 3: Targeted chemotherapy prior to surgery - Pancreatic Adenocarcinoma | Phase 2 | Completed | Medical College of Wisconsin | 229 | 2011-11-01 | 2023-08-14 |
| Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Regorafenib (BAY 73-4506), FOLFIRI, Placebo - Colorectal Cancer Metastatic | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 181 | 2011-04-07 | 2021-01-06 |
| A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer FOLFIRI, RO5083945, cetuximab - Colorectal Cancer | Phase 2 | Completed | Hoffmann-La Roche | 169 | 2011-04-01 | 2022-11-17 |
| 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma 4SC-201(Resminostat), FOLFIRI - Advanced Colorectal Carcinoma | Phase 1 / Phase 2 | Completed | 4SC AG | 17 | 2011-01-01 | 2015-04-01 |
| Second Line Chemotherapy for Advanced Pancreatic Cancer FOLFIRI - Pancreatic Adenocarcinoma | Phase 2 | Completed | Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | 50 | 2010-01-01 | 2012-03-05 |
| A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Vismodegib, FOLFOX, FOLFIRI - Ovarian Cancer, Basal Cell Carcinoma | Phase 2 | Completed | Genentech, Inc. | 19 | 2009-09-03 | 2026-05-08 |
| Prognostic Factors for Patients With Advanced Colorectal Cancer Treated With Cetuximab. Cetuximab, FOLFIRI - Colorectal Cancer | Phase 2 | Completed | Regione Lombardia | 54 | 2009-04-01 | 2014-05-12 |
Showing 20 of 32. Sign in to see all of them.
Colorectal Neoplasms (24) · Colonic Neoplasms (8) · Rectal Neoplasms (8) · Neoplasm Metastasis (5) · Neoplasms (4) · Adenocarcinoma (2) · Pancreatic Neoplasms (2) · Carcinoma (1) · Carcinoma, Basal Cell (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Non-Small-Cell Lung (1) · Exanthema (1) · Gastrointestinal Neoplasms (1) · Ovarian Neoplasms (1)
Amgen (4) · Cardiff Oncology (2) · Genentech, Inc. (2) · 4SC AG (1) · AbbVie (1) · Central European Cooperative Oncology Group (1) · Genzyme, a Sanofi Company (1) · Georgetown University (1) · Green Cross Corporation (1) · Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente (1) · Hoffmann-La Roche (1) · Hospices Civils de Lyon (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) · Karyopharm Therapeutics Inc (1)
United States (10) · Germany (5) · Italy (5) · France (4) · Spain (4) · South Korea (3) · Austria (2) · China (2) · Hungary (2) · Israel (2) · Poland (2) · Singapore (2) · United Kingdom (2) · Argentina (1) · Australia (1)
Roberto Labianca, MD (2) · Alberto Zaniboni, MD (1) · Armando Santoro, MD (1) · Changping Wu, M.D. (1) · Cynthia Sirard (1) · Douglas B. Evans, M.D., FACS (1) · Gabriel Capella (1) · Hanna Sanoff, MD (1) · Jennifer Low, M.D., Ph.D. (1) · Josina Reddy, MD, PhD (1)
PMID 22070868, PMID 22000810, PMID 22576338, PMID 23361051, PMID 23493136, PMID 23955585, PMID 24905030, PMID 30080723, PMID 30840064, PMID 31300973, PMID 31515083, PMID 32766143, PMID 34646387, PMID 35202974, PMID 35484400, PMID 36739879, PMID 37337155, PMID 38231047, PMID 39475591, PMID 41852303
2008 (2), 2014 (1), 2016 (1)